Prostatitis
Drug research and approvals for prostatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 8 studies of prostatitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 8
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗- Oxiblume:CoQ10 (Ralivia) Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)NCT07629505 · Not applicable · G.Gennimatas General Hospital · starts Jun 8, 2026
- Pain Type and Interstitial Cystitis/Bladder Pain Syndrome TreatmentNCT06299683 · Not applicable · Vanderbilt University Medical Center · starts May 1, 2024
- TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPSNCT06287970 · Not applicable · Jiani Wu · starts Mar 15, 2024
- Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective OutcomesNCT06115083 · Not applicable · Region Stockholm · starts Dec 1, 2023
- Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic PainNCT05868668 · Not applicable · The Cleveland Clinic · starts Sep 19, 2023
- Anti-inflammatory Drugs and Serum Prostate-Specific Antigen TestNCT05629494 · Phase 4 · Albany Medical College · starts Sep 27, 2022
- EPPIC: Easing Pelvic Pain Interventions Clinical Research ProgramNCT05127616 · Not applicable · State University of New York at Buffalo · starts Aug 10, 2022
- Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)NCT00499317 · Not reported · Boston Children's Hospital · starts Jan 15, 2007
Drug Pipeline
4 approved, 4 in phase 3, 7 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Ciprofloxacin, Flavoxate, Cephalexin anhydrous, Cefazolin
- Levofloxacin anhydrous
- Phase 3 DNA gyrase inhibitor
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Alfuzosin
- Phase 3 Adrenergic receptor alpha-1 agonist
- Pregabalin
- Phase 3 Voltage-gated calcium channel modulator
- Silodosin
- Phase 2 Alpha-1a adrenergic receptor antagonist
- Tamsulosin
- Phase 2 Adrenergic receptor alpha-1 antagonist
- Dutasteride
- Phase 2 Steroid 5-alpha-reductase inhibitor
- Pentosan polysulfate sodium
- Phase 2 Unknown
- Apremilast
- Phase 2 Phosphodiesterase 4 inhibitor
- Tanezumab
- Phase 2 Beta-nerve growth factor inhibitor
- Prulifloxacin
- Phase 2 Bacterial DNA gyrase inhibitor
- Cetirizine
- Early phase 1 Histamine H1 receptor antagonist
- Cromolyn
- Early phase 1 Unknown
How Its Trials Ended
87 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 35% met their primary endpoint, 13% missed it and 52% stopped early.
- Completed, result not reported3641%
- Status unknown1720%
- Ongoing1113%
- Met its primary endpoint89%
- Stopped: other or unclear67%
- Stopped: enrollment or feasibility56%
- Missed its primary endpoint33%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA